• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    7/21/22 8:09:05 AM ET
    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

     

    Gainers

    • Addex Therapeutics (NASDAQ:ADXN) shares increased by 46.1% to $1.34 during Thursday's pre-market session. The company's market cap stands at $8.4 million.
    • Tabula Rasa HealthCare (NASDAQ:TRHC) stock moved upwards by 14.61% to $2.98. The company's market cap stands at $77.0 million.
    • MoonLake (NASDAQ:MLTX) stock rose 14.1% to $6.31. The market value of their outstanding shares is at $233.0 million.
    • SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 13.17% to $2.92. The market value of their outstanding shares is at $59.9 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) shares increased by 10.4% to $5.2. The company's market cap stands at $209.8 million.
    • Endo International (NASDAQ:ENDP) shares increased by 9.99% to $0.46. The market value of their outstanding shares is at $107.1 million.

    Losers

    • LumiraDx (NASDAQ:LMDX) stock decreased by 17.1% to $1.75 during Thursday's pre-market session. The market value of their outstanding shares is at $443.9 million.
    • Verve Therapeutics (NASDAQ:VERV) shares fell 16.6% to $29.95. The market value of their outstanding shares is at $1.4 billion.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 9.34% to $1.36. The market value of their outstanding shares is at $17.6 million.
    • FIGS (NYSE:FIGS) stock fell 7.81% to $9.8. The market value of their outstanding shares is at $1.6 billion.
    • GreenLight Biosciences (NASDAQ:GRNA) shares declined by 7.05% to $2.11. The company's market cap stands at $259.9 million.
    • IMAC Holdings (NASDAQ:IMAC) stock fell 7.0% to $0.93. The company's market cap stands at $24.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ENDP
    $FIGS
    $GRNA

    CompanyDatePrice TargetRatingAnalyst
    FIGS Inc.
    $FIGS
    2/27/2026$17.00Sector Weight → Overweight
    KeyBanc Capital Markets
    FIGS Inc.
    $FIGS
    2/27/2026$9.00 → $15.00Market Perform
    Telsey Advisory Group
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    FIGS Inc.
    $FIGS
    11/7/2025$7.00 → $9.00Market Perform
    Telsey Advisory Group
    FIGS Inc.
    $FIGS
    10/15/2025$9.00Buy
    BTIG Research
    Olema Pharmaceuticals Inc.
    $OLMA
    10/8/2025$20.00Buy
    Guggenheim
    Olema Pharmaceuticals Inc.
    $OLMA
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    More analyst ratings

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FIGS, Inc. upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded FIGS, Inc. from Sector Weight to Overweight and set a new price target of $17.00

    2/27/26 8:21:04 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on FIGS, Inc. with a new price target

    Telsey Advisory Group reiterated coverage of FIGS, Inc. with a rating of Market Perform and set a new price target of $15.00 from $9.00 previously

    2/27/26 8:07:13 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Stifel initiated coverage on Olema Pharmaceuticals with a new price target

    Stifel initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $48.00

    2/11/26 7:52:37 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Mitchell Shawnte exercised 40,000 shares at a strike of $4.37, sold $945,750 worth of shares (39,767 units at $23.78) and sold $5,753 worth of Comon Stock (233 units at $24.69) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    3/5/26 8:00:07 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Oughtred Sarah was granted 342,760 shares, increasing direct ownership by 42% to 1,164,260 units (SEC Form 4)

    4 - FIGS, Inc. (0001846576) (Issuer)

    3/5/26 4:53:50 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Executive Chairman Hasson Heather L. was granted 214,225 shares, increasing direct ownership by 17% to 1,466,192 units (SEC Form 4)

    4 - FIGS, Inc. (0001846576) (Issuer)

    3/5/26 4:45:44 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

    3/3/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FIGS Releases Fourth Quarter and Full Year 2025 Financial Results

    Exceeded Top and Bottom Line Expectations Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026 FIGS, Inc. (NYSE:FIGS) (the "Company"), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Fourth Quarter 2025 Financial Highlights Net revenues were $201.9 million, an in

    2/26/26 4:05:00 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.

    SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/6/26 10:05:20 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/4/26 2:19:14 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/4/26 10:21:26 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Employ Inc. Appoints Jerry Jao as CEO

    DENVER, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Employ Inc., a leading provider of people-first, intelligent hiring solutions across JazzHR, Lever, and Jobvite, today announced the appointment of Jerry Jao as CEO. Jao is a successful serial entrepreneur who founded three businesses, including the AI-powered marketing and personalization SaaS company ReSci (Retention Science), acquired by Constant Contact in 2020. During his executive career, he first encountered Employ as a Lever customer and spent six years using the platform, gaining firsthand insight into how its innovation helps hiring managers stay organized and save time across the hiring process. Jao shared, "Hiring has never needed to

    2/18/26 8:00:00 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ENDP
    $FIGS
    $GRNA
    Financials

    Live finance-specific insights

    View All

    FIGS Releases Fourth Quarter and Full Year 2025 Financial Results

    Exceeded Top and Bottom Line Expectations Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026 FIGS, Inc. (NYSE:FIGS) (the "Company"), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Fourth Quarter 2025 Financial Highlights Net revenues were $201.9 million, an in

    2/26/26 4:05:00 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    FIGS Announces Date of Fourth Quarter and Full Year 2025 Earnings Release, Conference Call and Webcast

    FIGS, Inc. (NYSE:FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after U.S. markets close. FIGS management will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial and business results and outlook. Prior to the call, FIGS will publish a fourth quarter and full year 2025 financial highlights presentation on its investor relations website at https://ir.wearfigs.com/financials/quarterly-results/default.aspx. FIGS Fourth Quarter and Full Year 2025 Earnings and Conference Call

    2/5/26 4:05:00 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro

    12/4/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care